|
1
|
Kim MY, Hur J and Jeong S: Emerging roles
of RNA and RNA-binding protein network in cancer cells. BMB Rep.
42:125–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krecic AM and Swanson MS: hnRNP complexes:
composition, structure, and function. Curr Opin Cell Biol.
11:363–371. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dreyfuss G, Matunis MJ, Piñol-Roma S and
Burd CG: hnRNP proteins and the biogenesis of mRNA. Annu Rev
Biochem. 62:289–321. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Audic Y and Hartley RS:
Post-transcriptional regulation in cancer. Biol Cell. 96:479–498.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yisraeli JK: VICKZ proteins: a
multi-talented family of regulatory RNA-binding proteins. Biol
Cell. 97:87–96. 2005. View Article : Google Scholar
|
|
6
|
Shu L, Yan W and Chen X: RNPC1, an
RNA-binding protein and a target of the p53 family, is required for
maintaining the stability of the basal and stress-induced p21
transcript. Genes Dev. 20:2961–2972. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho SJ, Zhang J and Chen X: RNPC1
modulates the RNA-binding activity of, and cooperates with, HuR to
regulate p21 mRNA stability. Nucleic Acids Res. 38:2256–2267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyamoto S, Hidaka K, Jin D and Morisaki
T: RNA-binding proteins Rbm38 and Rbm24 regulate myogenic
differentiation via p21-dependent and -independent regulatory
pathways. Genes Cells. 14:1241–1252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan W, Zhang J, Zhang Y, Jung YS and Chen
X: p73 expression is regulated by RNPC1, a target of the p53
family, via mRNA stability. Mol Cell Biol. 32:2336–2348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin T, Cho SJ and Chen X: RNPC1, an
RNA-binding protein and a p53 target, regulates macrophage
inhibitory cytokine-1 (MIC-1) expression through mRNA stability. J
Biol Chem. 288:23680–23686. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Jun Cho S and Chen X: RNPC1, an
RNA-binding protein and a target of the p53 family, regulates p63
expression through mRNA stability. Proc Natl Acad Sci USA.
107:9614–9619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu E, Zhang J and Chen X: MDM2 expression
is repressed by the RNA-binding protein RNPC1 via mRNA stability.
Oncogene. 32:2169–2178. 2013. View Article : Google Scholar
|
|
13
|
Zhang J, Cho SJ, Shu L, Yan W, Guerrero T,
Kent M, Skorupski K, Chen H and Chen X: Translational repression of
p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev.
25:1528–1543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng SL, Xu J, Isaacs SD, Wiley K, Chang
B, Bleecker ER, Walsh PC, Trent JM, Meyers DA and Isaacs WB:
Evidence for a prostate cancer linkage to chromosome 20 in 159
hereditary prostate cancer families. Hum Genet. 108:430–435. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bar-Shira A, Pinthus JH, Rozovsky U,
Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A:
Multiple genes in human 20q13 chromosomal region are involved in an
advanced prostate cancer xenograft. Cancer Res. 62:6803–6807.
2002.PubMed/NCBI
|
|
16
|
Tanner MM, Grenman S, Koul A, Johannsson
O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent
amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
|
|
17
|
Korn WM, Yasutake T, Kuo WL, Warren RS,
Collins C, Tomita M, Gray J and Waldman FM: Chromosome arm 20q
gains and other genomic alterations in colorectal cancer metastatic
to liver, as analyzed by comparative genomic hybridization and
fluorescence in situ hybridization. Genes Chromosomes Cancer.
25:82–90. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Knösel T, Schlüns K, Stein U, Schwabe H,
Schlag PM, Dietel M and Petersen I: Genetic imbalances with impact
on survival in colorectal cancer patients. Histopathology.
43:323–331. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krackhardt AM, Witzens M, Harig S, Hodi
FS, Zauls AJ, Chessia M, Barrett P and Gribben JG: Identification
of tumor-associated antigens in chronic lymphocytic leukemia by
SEREX. Blood. 100:2123–2131. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carvalho B, Postma C, Mongera S, Hopmans
E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A,
Cuesta MA, et al: Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progression.
Gut. 58:79–89. 2009. View Article : Google Scholar
|
|
21
|
Hötte GJ, Linam-Lennon N, Reynolds JV and
Maher SG: Radiation sensitivity of esophageal adenocarcinoma: the
contribution of the RNA-binding protein RNPC1 and p21-mediated cell
cycle arrest to radioresistance. Radiat Res. 177:272–279. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ginestier C, Cervera N, Finetti P,
Esteyries S, Esterni B, Adélaïde J, Xerri L, Viens P, Jacquemier J,
Charafe-Jauffret E, et al: Prognosis and gene expression profiling
of 20q13-amplified breast cancers. Clin Cancer Res. 12:4533–4544.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Letessier A, Sircoulomb F, Ginestier C,
Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti
P, Zemmour C, et al: Frequency, prognostic impact, and subtype
association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13
amplifications in breast cancers. BMC Cancer. 6:2452006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue JQ, Xia TS, Liang XQ, Zhou W, Cheng L,
Shi L, Wang Y and Ding Q: RNA-binding protein RNPC1: Acting as a
tumor suppressor in breast cancer. BMC Cancer. 14:3222014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feldstein O, Ben-Hamo R, Bashari D, Efroni
S and Ginsberg D: RBM38 is a direct transcriptional target of E2F1
that limits E2F1-induced proliferation. Mol Cancer Res.
10:1169–1177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Léveillé N, Elkon R, Davalos V, Manoharan
V, Hollingworth D, Oude Vrielink J, le Sage C, Melo CA, Horlings
HM, Wesseling J, et al: Selective inhibition of microRNA
accessibility by RBM38 is required for p53 activity. Nat Commun.
2:5132011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang L, Luo Y and Wei J: Integrative
genomic analyses on Ikaros and its expression related to solid
cancer prognosis. Oncol Rep. 24:571–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Luo Y, Wei J and He S: Integrative
genomic analyses on IL28RA, the common receptor of
interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med.
25:807–812. 2010.PubMed/NCBI
|
|
29
|
Yang L, Wei J and He S: Integrative
genomic analyses on interferon-lambdas and their roles in cancer
prediction. Int J Mol Med. 25:299–304. 2010.PubMed/NCBI
|
|
30
|
Yu H, Yuan J, Xiao C and Qin Y:
Integrative genomic analyses of recepteur d’origine nantais and its
prognostic value in cancer. Int J Mol Med. 31:1248–1254.
2013.PubMed/NCBI
|
|
31
|
Wang M, Wei X, Shi L, Chen B, Zhao G and
Yang H: Integrative genomic analyses of the histamine H1 receptor
and its role in cancer prediction. Int J Mol Med. 33:1019–1026.
2014.PubMed/NCBI
|
|
32
|
Wang B, Chen K, Xu W, Chen D, Tang W and
Xia TS: Integrative genomic analyses of secreted protein acidic and
rich in cysteine and its role in cancer prediction. Mol Med Rep.
10:1461–1468. 2014.PubMed/NCBI
|
|
33
|
Wang B, Xu W, Tan M, Xiao Y, Yang H and
Xia TS: Integrative genomic analyses of a novel cytokine,
interleukin-34 and its potential role in cancer prediction. Int J
Mol Med. 35:92–102. 2015.
|
|
34
|
Kumar S, Nei M, Dudley J and Tamura K:
MEGA: A biologist-centric software for evolutionary analysis of DNA
and protein sequences. Brief Bioinform. 9:299–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Z: PAML: aA program package for
phylogenetic analysis by maximum likelihood. Comput Appl Biosci.
13:555–556. 1997.PubMed/NCBI
|
|
36
|
Yang Z, Nielsen R, Goldman N and Pedersen
AM: Codon-substitution models for heterogeneous selection pressure
at amino acid sites. Genetics. 155:431–449. 2000.PubMed/NCBI
|
|
37
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011.
View Article : Google Scholar :
|
|
38
|
Parkinson H, Sarkans U, Shojatalab M,
Abeygunawardena N, Contrino S, Coulson R, Farne A, Lara GG,
Holloway E, Kapushesky M, et al: ArrayExpress - a public repository
for microarray gene expression data at the EBI. Nucleic Acids Res.
33:D553–D555. 2005. View Article : Google Scholar
|
|
39
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: a new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xue JQ, Xia TS, Liang XQ, Zhou W, Cheng L,
Shi L, Wang Y and Ding Q: RNA-binding protein RNPC1: Acting as a
tumor suppressor in breast cancer. BMC Cancer. 14:3222014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Renjie W and Haiqian L: MiR-132, miR-15a
and miR-16 synergistically inhibit pituitary tumor cell
proliferation, invasion and migration by targeting Sox5. Cancer
Lett. 356:568–578. 2015. View Article : Google Scholar
|
|
42
|
Pei XH, Lv XQ and Li HX: Sox5 induces
epithelial to mesenchymal transition by transactivation of Twist1.
Biochem Biophys Res Commun. 446:322–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kang KA, Kim KC, Bae SC and Hyun JW:
Oxidative stress induces proliferation of colorectal cancer cells
by inhibiting RUNX3 and activating the Akt signaling pathway. Int J
Oncol. 43:1511–1516. 2013.PubMed/NCBI
|
|
44
|
Xu HW, Ren F, Yu YM and Cai CZ: Runx3
expression in lymph nodes with metastasis is associated with the
outcome of gastric cancer patients. Oncol Lett. 2:1275–1279.
2011.
|
|
45
|
Yu GP, Ji Y, Chen GQ, Huang B, Shen K, Wu
S and Shen ZY: Application of RUNX3 gene promoter methylation in
the diagnosis of non-small cell lung cancer. Oncol Lett. 3:159–162.
2012.PubMed/NCBI
|
|
46
|
Han YX and Liang DY: The role of the tumor
suppressor RUNX3 in giant cell tumor of the bone. Int J Oncol.
40:673–678. 2012.
|
|
47
|
Bian J, Li B, Zeng X, Hu H, Hong Y, Ouyang
H, Zhang X, Wang Z, Zhu H, Lei P, et al: Mutation of TGF-β receptor
II facilitates human bladder cancer progression through altered
TGF-β1 signaling pathway. Int J Oncol. 43:1549–1559.
2013.PubMed/NCBI
|
|
48
|
Liu KC, Lin BS, Zhao M, Wang KY and Lan
XP: Cutl1: A potential target for cancer therapy. Cell Signal.
25:349–354. 2013. View Article : Google Scholar
|
|
49
|
Claudius AK, Kankipati CS, Kilari RS,
Hassan S, Guest K, Russell ST, Perry CJ, Stark LA and Nicholl ID:
Identification of aspirin analogues that repress NF-κB signalling
and demonstrate anti-proliferative activity towards colorectal
cancer in vitro and in vivo. Oncol Rep. 32:1670–1680.
2014.PubMed/NCBI
|
|
50
|
Zhang J, Kou YB, Zhu JS, Chen WX and Li S:
Knockdown of HMGB1 inhibits growth and invasion of gastric cancer
cells through the NF-κB pathway in vitro and in vivo. Int J Oncol.
44:1268–1276. 2014.PubMed/NCBI
|
|
51
|
Guan Z, Ding C, Du Y, Zhang K, Zhu JN,
Zhang T, He D, Xu S, Wang X and Fan J: HAF drives the switch of
HIF-1α to HIF-2α by activating the NF-κB pathway, leading to
malignant behavior of T24 bladder cancer cells. Int J Oncol.
44:393–402. 2014.
|
|
52
|
Yu L, Mu Y, Sa N, Wang H and Xu W: Tumor
necrosis factor α induces epithelial-mesenchymal transition and
promotes metastasis via NF-κB signaling pathway-mediated TWIST
expression in hypopharyngeal cancer. Oncol Rep. 31:321–327.
2014.
|
|
53
|
Xue M, Li X, Wu W, Zhang S, Wu S, Li Z and
Chen W: Upregulation of long non-coding RNA urothelial carcinoma
associated 1 by CCAAT/enhancer binding protein α contributes to
bladder cancer cell growth and reduced apoptosis. Oncol Rep.
31:1993–2000. 2014.PubMed/NCBI
|
|
54
|
Weng W, Wang M, Xie S, Long Y, Li F, Sun
F, Yu Y and Li Z: YY1-C/EBPα-miR34a regulatory circuitry is
involved in renal cell carcinoma progression. Oncol Rep.
31:1921–1927. 2014.PubMed/NCBI
|
|
55
|
Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y
and Zheng X: MicroRNA-1 and microRNA-499 downregulate the
expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep.
28:701–706. 2012.PubMed/NCBI
|
|
56
|
Shaikhibrahim Z and Wernert N: ETS
transcription factors and prostate cancer: The role of the family
prototype ETS-1 (Review). Int J Oncol. 40:1748–1754.
2012.PubMed/NCBI
|
|
57
|
Metzeler KH, Hummel M, Bloomfield CD,
Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M,
Marcucci G, Whitman SP, et al Cancer and Leukemia Group B; German
AML Cooperative Group: An 86-probe-set gene-expression signature
predicts survival in cytogenetically normal acute myeloid leukemia.
Blood. 112:4193–4201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Anders CK, Acharya CR, Hsu DS, Broadwater
G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, et
al: Age-specific differences in oncogenic pathway deregulation seen
in human breast tumors. PLoS One. 3:e13732008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schmidt M, Böhm D, von Törne C, Steiner E,
Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H and Gehrmann M: The
humoral immune system has a key prognostic impact in node-negative
breast cancer. Cancer Res. 68:5405–5413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jain AN, Chin K, Børresen-Dale AL,
Erikstein BK, Eynstein Lonning P, Kaaresen R and Gray JW:
Quantitative analysis of chromosomal CGH in human breast tumors
associates copy number abnormalities with p53 status and patient
survival. Proc Natl Acad Sci USA. 98:7952–7957. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Smith JJ, Deane NG, Wu F, Merchant NB,
Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al:
Experimentally derived metastasis gene expression profile predicts
recurrence and death in patients with colon cancer.
Gastroenterology. 138:958–968. 2010. View Article : Google Scholar
|
|
63
|
Laurent C, Valet F, Planque N, Silveri L,
Maacha S, Anezo O, Hupe P, Plancher C, Reyes C, Albaud B, et al:
High PTP4A3 phosphatase expression correlates with metastatic risk
in uveal melanoma patients. Cancer Res. 71:666–674. 2011.
View Article : Google Scholar
|
|
64
|
Director’s Challenge Consortium for the
Molecular Classification of Lung Adenocarcinoma; Shedden K, Taylor
JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S,
Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based
survival prediction in lung adenocarcinoma: a multi-site, blinded
validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hammerman PS, Lawrence MS, Voet D, Jing R,
Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES,
Gabriel S, et al Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar
|
|
66
|
Yamauchi M, Yamaguchi R, Nakata A, Kohno
T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y,
et al: Epidermal growth factor receptor tyrosine kinase defines
critical prognostic genes of stage I lung adenocarcinoma. PLoS One.
7:e439232012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tomida S, Koshikawa K, Yatabe Y, Harano T,
Ogura N, Mitsudomi T, Some M, Yanagisawa K and Takahashi T, Osada H
and Takahashi T: Gene expression-based, individualized outcome
prediction for surgically treated lung cancer patients. Oncogene.
23:5360–5370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar
|
